

Remarks

Currently Claims 1-22 are pending.

The specification is amended to include an abstract on a separate page and to recite cross-reference to related applications.

Claims 23-28 are canceled. Claims 4-12, 14, 16-17 and 19-20 are amended herein. The claims are amended to remove multiple dependencies for the purpose of reducing fees. The amendments do not narrow the scope of the claims and no new matter is added.

Notice of Co-Pending Applications

The Examiner is respectfully requested to take note of the following co-pending applications which are commonly owned.

10/362146	2/19/2003
10/433881	6/5/2003
10/433884	6/5/2003
10/468729	8/22/2003
10/473751	10/1/2003
10/473197	9/24/2003
10/473196	9/24/2003
10/473491	9/25/2003
10/487968	2/26/2004
10496358	5/20/2004

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 31 March, 2005
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
email: Lorie.A.Morgan@GSK.com